Understanding Response Discordance in Rectal Cancer

Accurately evaluating the effects of rectal cancer neoadjuvant therapy is vital for optimizing surgical and oncological management. Although clinicians use advanced imaging and physical exams to gauge response, these clinical assessments often differ from final pathologic findings. Consequently, understanding this discordance helps medical teams manage expectations and refine long-term care plans.

The Impact of Rectal Cancer Neoadjuvant Therapy

Researchers recently analyzed 180 patients with locally advanced rectal cancer to compare clinical and pathologic responses. The study found that clinical evaluations suggested a complete or near-complete response in nearly half of the participants. However, pathologic examination confirmed this high response level in only 35% of the cases. This moderate concordance indicates that clinical tools frequently overestimate the actual degree of tumor regression. For instance, discordance occurred in over 28% of patients, mostly due to clinical overestimation of the treatment effect. Furthermore, the study demonstrated that pathologic response is a much stronger predictor of survival. Patients achieving a pathologic complete response showed a 3-year disease-free survival rate of 89.2%. In contrast, those without such a response had a rate of only 69.1%. Interestingly, clinical response status alone did not significantly correlate with overall survival or disease-free survival outcomes.

Frequently Asked Questions

Why does clinical response often differ from pathologic response?

Clinical assessments rely on imaging and exams that may miss microscopic residual disease. Pathologic response is determined by a microscopic examination of the entire resected specimen, which is more accurate.

Is pathologic complete response necessary for a good prognosis?

While not strictly necessary, achieving a pathologic complete response is strongly associated with significantly improved disease-free and overall survival rates compared to incomplete responses.

Should clinicians rely solely on clinical response for monitoring?

No, because clinical response can overestimate the treatment effect. Pathologic verification remains the gold standard for predicting long-term outcomes and guiding further therapy.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Erken AA et al. Clinical-Pathologic Response Discordance After Neoadjuvant Therapy in Rectal Cancer and Its Prognostic Implications. Asia Pac J Clin Oncol. 2026 Apr 29. doi: 10.1111/ajco.70119. PMID: 42056758.


2. Jalilian M et al. Pathologic response to neoadjuvant treatment in locally advanced rectal cancer and impact on outcome. J Gastrointest Oncol. 2016;7(4):603-608.


3. Maas M et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835-844.